rs7799039 — LEP G-2548A

The Leptin Promoter Variant That Amplifies Your Fat-Signaling Thermostat

Leptin is the hormone adipose tissue sends to the hypothalamus to announce that energy stores are adequate — its central function is to suppress appetite and increase energy expenditure when fat stores are full. The G-2548A polymorphism (rs7799039) sits in the promoter region of the LEP gene, 2,548 base pairs upstream of the translation start site, at a regulatory position that controls how actively the gene is transcribed. Carriers of the A allele make more leptin — but chronic overproduction of any hormone typically leads to receptor desensitization, and that is precisely where this variant's metabolic consequences unfold.

The LEP gene sits on chromosome 7 (7q32.1) on the plus strand. The G-2548A variant is a straightforward G-to-A transition in the promoter; it does not change the leptin protein itself but alters how much of it is produced by fat cells.

The Mechanism

A landmark 2002 study by Hoffstedt et al.¹¹ Hoffstedt et al.
"A polymorphism in the leptin promoter region (-2548 G/A) influences gene expression and adipose tissue secretion of leptin." Obesity Research, 2002 demonstrated the functional consequence directly in human adipose tissue. In 39 non-obese women, AA homozygotes showed:

• 60% higher leptin mRNA in adipose tissue (74 vs 46 amol/μg RNA, p=0.01)
• Twice the adipose leptin secretion rate (1,158 vs 626 ng per 2h per 10⁷ cells, p=0.02)
• 50% higher serum leptin (14.5 vs 9.7 ng/ml, p=0.02)

These differences remained significant after adjusting for BMI, confirming they reflect genetically driven differences in transcriptional activity rather than adiposity. The mechanism involves nuclear proteins forming stronger protein-DNA complexes with the -2548A variant, enhancing transcription factor binding and boosting promoter activity.

Chronically elevated leptin — hyperleptinemia²² hyperleptinemia
Persistently high leptin levels that cause the hypothalamic leptin receptor to downregulate, blunting the satiety signal — leads to leptin resistance. This paradox (high leptin, inadequate signal) mirrors insulin resistance: the hormone is abundant but tissues stop responding. The downstream consequences include impaired satiety signaling, increased food intake, and reduced energy expenditure — the metabolic triad that promotes obesity.

The Evidence

Metabolic outcomes: Multiple studies link the A allele to adverse metabolic profiles. In a Malaysian cohort of 300 subjects, AA genotype carriers with T2DM³³ AA genotype carriers with T2DM
Ali et al. 2022, LEP G2548A polymorphism associated with leptin and insulin resistance in Malaysian T2DM patients showed significantly higher BMI, serum leptin, and fasting insulin compared to GG carriers. A systematic review and pooled analysis of 18,984 subjects across 11 studies⁴⁴ 18,984 subjects across 11 studies
Khaki-Khatibi et al. 2022, Gene polymorphism of leptin and risk for heart disease, obesity, and high BMI concluded that AA allele carriers face increased risk for heart disease, high BMI, and obesity.

Diet response: The A allele markedly blunts lipid improvement with dietary intervention. In 122 obese patients⁵⁵ 122 obese patients
Primo et al. 2021, Leptin gene polymorphism rs7799039 associated with lipid profile changes on hypocaloric diet randomized to a partial meal-replacement hypocaloric diet, GG carriers reduced triglycerides by 15.3 mg/dL while GA/AA carriers reduced them by only 3.7 mg/dL — a four-fold difference. Total cholesterol fell 25.0 mg/dL in GG vs 8.1 mg/dL in A-allele carriers; LDL fell 20.7 vs 5.4 mg/dL.

Lipids during pregnancy: A prospective Brazilian cohort study of 154 pregnant women⁶⁶ 154 pregnant women
Farias et al. 2020, rs7799039 associated with serum lipid concentrations during pregnancy found AA genotype carriers reported higher fat and total energy intake and had greater triglyceride increases throughout pregnancy. Importantly, adjusting for dietary fat intake did not eliminate the genotype-lipid association, suggesting a direct genetic effect on lipid metabolism beyond behavioral differences.

Cancer association: A meta-analysis of 31 case-control studies with 25,799 subjects⁷⁷ 31 case-control studies with 25,799 subjects
Tang et al. 2019, Leptin rs7799039 polymorphism and cancer risk meta-analysis found A-allele carriers had OR 1.16–1.22 for overall cancer susceptibility, with elevated risk for prostate cancer (OR 1.24) and hematopoietic malignancies in Asian populations.

Note on evidence inconsistency: Population studies show heterogeneous results — some find no association between G2548A and obesity or BMI in isolation, particularly in Turkish and some European cohorts. The strongest and most consistent signals come from mechanistic studies (adipose tissue directly), obese clinical cohorts, and dietary intervention trials. The evidence is moderate, not established.

Practical Actions

For GG genotype carriers, standard dietary advice applies — no genotype-specific modification is needed. For A allele carriers (AG and AA), the primary implication is that standard caloric restriction produces blunted lipid improvements compared to GG individuals, and chronically elevated leptin production sets up a physiological context favoring leptin resistance. Limiting dietary saturated fat and refined carbohydrates specifically targets the triglyceride and insulin sensitivity pathways most affected by this variant. For AA homozygotes, the effect is dose-dependent and warrants closer monitoring of fasting triglycerides, glucose, and insulin.

Interactions

The most studied interaction involves LEP G2548A combined with LEPR Q223R (rs1137101). A Tunisian study of 329 subjects found that the combined haplotype carrying the 2548A allele and LEPR 223R (AR haplotype) increased obesity risk to OR 3.36 (p<0.001), substantially higher than either variant alone. The 2548A + 223Q haplotype also raised obesity risk (OR 2.56, p=0.010). This interaction makes biological sense: elevated leptin production (LEP A allele) combined with impaired receptor binding (LEPR R allele at position 223) compounds both branches of the leptin signaling circuit simultaneously.

A second LEP promoter variant, rs2167270 (G-19A), has been studied in combination with rs7799039. These two LEP promoter variants can combine in haplotypes that affect leptin levels and metabolic syndrome markers, though the interaction evidence is less robust than for LEP-LEPR combinations.